Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Revvity Inc (RVTY) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Revvity Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.85, while Revvity Inc trades at $116.53 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Revvity Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPIRVTY
Sector
Income / Options OverlayTechnology
52-Week High
$49.54$117.75
52-Week Low
$37.98$82.26
Market Cap
$12.91B
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.88 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The ETF generates substantial income through weekly dividend distributions averaging $0.20-0.21 per share, funded by its covered call strategy on concentrated AI and tech holdings. Recent news highlights the fund's transition to weekly distributions and ongoing discussions about its aggressive income approach.

The high-yield strategy presents income opportunities but carries significant risk from NAV erosion during market downturns. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of 25% yields and concentrated exposure to volatile tech names warrant cautious positioning. The covered call approach limits upside potential while providing consistent cash flow.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY